| Literature DB >> 31719794 |
Ping Li1,2,3, YanZhen Xu1,4, Qinle Zhang5, Yu Li6, Wenxian Jia1,7, Xiao Wang8, Zhibin Xie1, Jiayi Liu1,2,3, Dong Zhao1, Mengnan Shao1, Suixia Chen1,4, Nanfang Mo8, Zhiwen Jiang8, Liuyan Li8, Run Liu8, Wanying Huang8, Li Chang8, Siyu Chen8, Hongtao Li9, Wenpu Zuo8, Jiaquan Li8, Ruoheng Zhang10, Xiaoli Yang1,9.
Abstract
BACKGROUND: Radiation sensitive 52 (RAD52) is an important protein that mediates DNA repair in tumors. However, little is known about the impact of RAD52 on hepatocellular carcinoma (HCC). We investigated the expression of RAD52 and its values in HCC. Some proteins that might be coordinated with RAD52 in HCC were also analyzed.Entities:
Keywords: DNA repair; Diagnostic marker; Hepatocellular carcinoma; Molecular interaction; RAD52
Year: 2019 PMID: 31719794 PMCID: PMC6836504 DOI: 10.1186/s12935-019-0996-6
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Correlation between the factors and clinicopathological characteristics in the Chinese population (n = 70)
| Clinical features | Case | RAD52 positive rate (%; mean ± SD) | P-value |
|---|---|---|---|
| Sample | |||
| HCC | 70 | 65.600 ± 25.079 | P < 0.05* |
| Adjacent tissue | 70 | 48.057 ± 26.928 | |
| Age (years) | |||
| ≤ 45 | 28 | 57.036 ± 28.299 | P < 0.05* |
| > 45 | 42 | 71.310 ± 21.157 | |
| Gender | |||
| Male | 61 | 66.918 ± 24.841 | P > 0.05 |
| Female | 9 | 56.667 ± 26.339 | |
| Smoking | |||
| Yes | 35 | 63.486 ± 26.579 | P > 0.05 |
| No | 35 | 67.714 ± 23.681 | |
| Drinking | |||
| Yes | 38 | 65.316 ± 26.366 | P > 0.05 |
| No | 32 | 65.938 ± 23.876 | |
| HBsAg infection | |||
| Yes | 50 | 68.700 ± 25.948 | P > 0.05 |
| No | 20 | 57.850 ± 21.431 | |
| AFP (ng/ml) | |||
| ≤ 20 | 20 | 66.100 ± 21.885 | P > 0.05 |
| > 20 | 50 | 65.400 ± 26.454 | |
| Tumor size (cm) | |||
| ≤ 5 | 12 | 53.750 ± 23.848 | P > 0.05 |
| > 5 | 6 | 45.000 ± 32.711 | |
| Unknown | 52 | 70.712 ± 22.667 | |
| Clinical stage | |||
| I + II | 32 | 63.656 ± 25.299 | P > 0.05 |
| III + IV | 38 | 67.237 ± 25.113 | |
| ALT | |||
| ≤ 40 | 38 | 64.083 ± 27.055 | P > 0.05 |
| > 40 | 32 | 70.517 ± 22.494 | |
| AST | |||
| ≤ 40 | 28 | 65.280 ± 25.370 | P > 0.05 |
| > 40 | 42 | 68.000 ± 25.263 | |
RAD52 radiation sensitive 52, HCC hepatocellular carcinoma, AFP alpha fetoprotein, HBsAg hepatitis B surface antigen, ALT glutamic-pyruvic transaminase, AST aspartate transaminase, SD standard deviation
* P < 0.05
Fig. 1Data mining of RAD52 in the TCGA database. a RAD52 mRNA expression in HCC tissues and normal tissues. RNA-seq data were quantified using RSEM. Significant differences were observed between HCC tissues and normal tissues. Higher expression of RAD52 in HCC tissues than in normal tissues was obtained (***P ≤ 0.001). b Receiver-operation characteristic (ROC) curve of RAD52. The AUC of RAD52 was 0.704. The sensitivity and specificity were 61.20% and 71.00%, respectively. c Overall survival (OS) curve according to RAD52 expression in HCC. d Recurrence-free survival (RFS) of RAD52 expression in HCC
Correlation between the factors and clinicopathologic characteristics in HCC in TCGA dataset (n = 363)
| Clinical features | Case | RAD52 level (RSEM; mean ± SD) | P value |
|---|---|---|---|
| Sample | |||
| LIHC | 363 | 6.4606 ± 0.6778 | P < 0.05* |
| Normal | 50 | 6.0250 ± 0.5742 | |
| Age at diagnosis (years) | |||
| > 45 | 314 | 6.4371 ± 0.6918 | P > 0.05 |
| ≤ 45 | 48 | 6.6329 ± 0.5475 | |
| Unknown | 1 | ||
| Gender | |||
| Male | 246 | 6.3721 ± 0.6948 | P < 0.05* |
| Female | 117 | 6.6466 ± 0.6020 | |
| The AFP in serum | |||
| > 20 ng/ml | 129 | 6.5403 ± 0.6778 | P > 0.05 |
| ≤ 20 ng/ml | 143 | 6.4050 ± 0.6319 | |
| Unknown | 91 | ||
| Clinical stage | |||
| I–II | 251 | 6.4353 ± 0.6493 | P > 0.05 |
| III–IV | 88 | 6.5033 ± 0.7782 | |
| Unknown | 24 | ||
| Child–Pugh classification | |||
| A | 213 | 6.4195 ± 0.7080 | P > 0.05 |
| B | 21 | 6.4685 ± 0.5537 | |
| C | 1 | ||
| Unknown | 128 | ||
| HBsAg infection | |||
| Yes | 226 | 6.4981 ± 0.6733 | P > 0.05 |
| No | 122 | 6.4139 ± 0.6543 | |
| Unknown | 15 | ||
| Lymph node | |||
| N0 | 246 | 6.4788 ± 0.6713 | P > 0.05 |
| N1 | 3 | 6.8001 ± 1.0916 | |
| Unknown | 114 | ||
| Metastasis | |||
| M0 | 260 | 6.4512 ± 0.6827 | P > 0.05 |
| M1 | 4 | 6.0975 ± 0.5427 | |
| Unknown | 99 | ||
TCGA The Cancer Genome Atlas, LIHC liver hepatocellular carcinoma, HCC hepatocellular carcinoma, RSEM RNA-seq by expectation-maximization, RAD52 radiation sensitive 52, AFP alpha fetoprotein, HBsAg hepatitis B surface antigen, SD standard deviation
* P < 0.05
Fig. 2RAD52 expression was significantly upregulated in Chinese HCC tissues compared to their paired adjacent (peritumoral) tissues. a mRNA expression of RAD52 detected by qRT-PCR in HCC. Upregulated mRNA was shown in HCC tissues (*P ≤ 0.05). b RAD52 protein levels were measured by Western blotting. Lanes 1, 3, and 5 represent cancer tissues. Lanes 2, 4, and 6 represent adjacent tissues. Increased RAD52 protein expression was observed in HCC tissues. c RAD52 immunohistochemical testing in 70 paired HCC tissues and adjacent nontumor tissues. Representative IHC images of RAD52 expression are shown in the panel. The left is HCC tissues with high expression. The right is nontumor tissues with low expression
Fig. 3The functional role of RAD52 in HCC cell lines. a Expression level of RAD52 in human HCC cell lines including SMCC-7721 (7721), MHCC 97H (97H), MHCC 97L (97L), Huh7, HepG2 (G2), HCC-LM3 (LM3), and BEL7404 (7404) measured by Western blotting. Compared with the highest expression level of RAD52 in 7404, expression of RAD52 in Huh7 was lowest among these cells (P < 0.05, quantified by ImageJ). b Western blotting and qRT-PCR were used to detect RAD52 expression in RAD52-overexpression (OE)-transfected Huh7 cells. c CCK-8 test suggested that RAD52-OE in Huh7 cells could promote cell proliferation (P < 0.05). d Scratch wound assay showed that RAD52-OE in Huh7 cells could promote cell migration
Fig. 6PPI network (with module analyses) and docking results between RAD52 and its interactors. The PDB numbers of RAD52, RAD51, XRCC6, and CFL1 were 1kn0, 5h1c, 1jey, 1q8g, respectively. (https://www.rcsb.org/) a The enrichment and pathways analysis. b PPI network of RAD52 and its interactome. The red node represents the core protein. Blue nodes represent the important DSB repair protein, while the gray nodes represent predicted functional node partners. c Core module for RAD52 and its interaction partners. d RAD52–XRCC6 complex, e RAD52–CFL1 complex, f RAD52–RAD51 complex
Fig. 4Data mining of RAD51, XRCC6 and CFL1. a RSEM of RAD51, XRCC6 and CFL1 in HCC tissues and normal tissues in the TCGA database. Higher expression of RAD51, XRCC6 and CFL1 was observed in HCC tissues ***P ≤ 0.001). b ROC curves of RAD52, RAD51, XRCC6, CFL1, and combined models in diagnosing HCC. Each AUC of the combined model was larger than that of RAD52. The AUC of the combined model (RAD52 and RAD51) was largest in all models (0.924). In each picture, the red solid ROC curve represented the combined model of RAD52 and another protein (the green solid). The blue solid ROC curve represents RAD52. The gray solid represents the reference line. c mRNA expression of RAD51, XRCC6, and CFL1 was confirmed in HCC tissues and adjacent tissues. Upregulated mRNA levels of RAD51, XRCC6, and CFL1 were observed in HCC tissues (*P ≤ 0.05)
Fig. 5Survival curves of RAD51, XRCC6, and CFL1 in HCC. a–c Overall survival (OS) curves. Significant differences between high and low expression of RAD51, XRCC6, and CFL1 were found in OS. Higher RAD51, XRCC6, CFL1 have significantly poorer OS (*P ≤ 0.05). d–f Recurrence-free survival (RFS). Higher XRCC6 or CFL1 was not associated with shorter RFS (P > 0.05). However, higher RAD51 levels have significantly poorer RFS (*P ≤ 0.05)